Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study-Reference-Cited by-同舟云学术

Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study

Published:2012-09-06 Issue:4 Volume:96 Page:485-491
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Ito Yoshikazu,Wakita Atsushi,Takada Satoru,Mihara Masahiro,Gotoh Moritaka,Ohyashiki Kazuma,Ohtake Shigeki,Miyawaki Shuichi,Ohnishi Kazunori,Naoe Tomoki

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-012-1165-z.pdf

Reference26 articles.

1. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29:487–94.

2. Dombret H, Raffoux E, Gardin C. Acute myeloid leukemia in the elderly. Semin Oncol. 2008;35:430–8.

3. Buchner T, Berdel WE, Wormann B, Schoch C, Haferlach T, Schnittger S, et al. Treatment of older patients with AML. Crit Rev Oncol Hematol. 2005;56:247–59.

4. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244–54.

5. Larson RA. Current use and future development of gemtuzumab ozogamicin. Semin Hematol. 2001;38(suppl 6):24–31.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advance of structural modification of nucleosides scaffold;European Journal of Medicinal Chemistry;2021-03

2. A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients’ trial;European Journal of Haematology;2015-05-06

3. New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach;Clinical Cancer Research;2014-09-30

4. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia;International Journal of Hematology;2013-05-14